Proactive news headlines: Sensyne Health, Custodian REIT, Blackbird…

0
22

Sensyne Health PLC (AIM:SENS) said a licence and development partner has received European regulatory certification for a COVID-19 antigen testing system that uses Sensyne’s AI-powered MagnifEye technology.


Custodian REIT PLC (LSE:CREI) has purchased an industrial unit on the outskirts of York for GBP2.962mln.


Blackbird PLC (AIM:BIRD, OTCQX:BBRDF), the cloud native video editing platform operator, has launched its core technology licensing solution, ‘Powered by Blackbird’. By licensing the company’s core video technology, companies can build their own cloud native video platforms including frame accurate, renderless editing in a browser with bandwidth from just 2 Mb/s (megabits per second).


W Resources PLC (AIM:WRES) announced record tungsten recovery rates, grades and production in the third quarter from the La Parrilla mine in Spain and the AIM-quoted company said it expects output in the fourth quarter to be even better.


Landore Resources Ltd (AIM:LND) said it will re-evaluate its B4-7 and VW nickel-copper-cobalt-PGEs deposits on its Junior Lake Property in Canada as escalating prices for metals used in batteries have substantially increased the value of the resources.


Condor Gold PLC (AIM:CNR, TSX:COG, OTC:CNDGF) announced the completion of an in-fill drilling programme on the high-grade La Mestiza Open Pit, part of its La India project in Nicaragua.


Shanta Gold Ltd reported steady gold production in the third quarter, during a period when the company continued to intercept high gold grades at its West Kenya project and increased its resource estimate at the New Luika gold mine in Tanzania.


Tungsten West PLC (AIM:TUN), which plans to restart production at the Hemerdon tungsten-tin mine in south Devon, made its debut on London’s Alternative Investment Market today.


NetScientific PLC (AIM:NSCI) noted that the temporary suspension by portfolio company PDS Biotechnology Corporation (NASDAQ:PDSB) of patient recruitment for one of their clinical studies is not expected to affect the overall timing of clinical data.

LEAVE A REPLY

Please enter your comment!
Please enter your name here